<div id="readability-page-1"><p><span>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report)</span> had its price objective boosted by Wells Fargo &amp; Company  from $212.00 to $230.00 in a research note issued on Friday,MarketScreener reports. The firm presently has an &#34;overweight&#34; rating on the stock. Wells Fargo &amp; Company's price objective suggests a potential upside of 8.67% from the stock's current price.</p><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p>Several other research firms have also recently issued reports on JNJ. Argus  set a $210.00 price target on Johnson &amp; Johnson in a research note on Wednesday, October 15th. Daiwa America raised shares of Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Monday, October 20th. Sanford C. Bernstein raised their price objective on shares of Johnson &amp; Johnson from $172.00 to $193.00 and gave the company a &#34;market perform&#34; rating in a research note on Monday, October 6th. Raymond James Financial boosted their target price on Johnson &amp; Johnson from $174.00 to $209.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, October 15th. Finally, Cowen  reaffirmed a &#34;buy&#34; rating on shares of Johnson &amp; Johnson in a research note on Tuesday, October 14th. Four analysts have rated the stock with a Strong Buy rating, fourteen have issued  a Buy rating and nine have issued  a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $207.55.</p><div><p><span></span><span>Get <strong>Johnson &amp; Johnson</strong> alerts:</span></p></div><p><b>Check Out Our Latest Report on Johnson &amp; Johnson</b></p><h2>Johnson &amp; Johnson Trading Up 0.8%</h2><ul><li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li></ul><p>Shares of JNJ stock traded up $1.64 during mid-day trading on Friday, reaching $211.65. The company's stock had a trading volume of 6,919,148 shares, compared to its average volume of 9,422,986. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson &amp; Johnson has a 12-month low of $140.68 and a 12-month high of $212.27. The firm has a market capitalization of $509.93 billion, a PE ratio of 20.43, a price-to-earnings-growth ratio of 2.34 and a beta of 0.36. The company's 50 day simple moving average is $196.09 and its 200-day simple moving average is $177.08. </p><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson &amp; Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, research analysts predict that  Johnson &amp; Johnson will post 10.58 EPS for the current fiscal year. </p><h2>Institutional Trading of Johnson &amp; Johnson</h2><ul><li>3 Smart Defensive Stocks for an Uneasy Market</li></ul><p>Institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC increased its position in  Johnson &amp; Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares during the period.  United Bank boosted its position in  Johnson &amp; Johnson by 110.7% in the first quarter. United Bank now owns 9,279 shares of the company's stock valued at $1,539,000 after buying an additional 4,876 shares in the last quarter.  Cookson Peirce &amp; Co. Inc. acquired a new stake in shares of  Johnson &amp; Johnson in the first quarter valued at $208,000.  EverSource Wealth Advisors LLC lifted its position in shares of  Johnson &amp; Johnson by 10.5% during the first quarter. EverSource Wealth Advisors LLC now owns 19,646 shares of the company's stock worth $3,258,000 after purchasing an additional 1,863 shares in the last quarter.  Finally, Forvis Mazars Wealth Advisors LLC increased its stake in shares of  Johnson &amp; Johnson by 37.6% in the 1st quarter. Forvis Mazars Wealth Advisors LLC now owns 58,656 shares of the company's stock valued at $9,728,000 after buying an additional 16,019 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Johnson &amp; Johnson Company Profile</h2> (Get Free Report)<p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>What Are Trending Stocks? Trending Stocks Explained</li><li>Why Amazon Could Be a $300 Stock Within Weeks</li><li>What Investors Need to Know About Upcoming IPOs</li><li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li><li>How to buy stock: A step-by-step guide for beginners </li><li>MarketBeat Week in Review – 12/8 - 12/12</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Wells Fargo & Company raised its target price for Johnson & Johnson (NYSE:JNJ) from $212.00 to $230.00, giving the stock an "overweight" rating. This suggests an 8.67% potential upside from the current price. Several other firms have also updated their ratings and price targets for JNJ recently. The stock has a consensus rating of "Moderate Buy" and a consensus target price of $207.55.</p>

Johnson & Johnson (NYSE:JNJ) Given New $230.00 Price Target at Wells Fargo & Company